General “News” category

An Update on the Burn Pits Accountability Act of 2019

2019-07-17T14:08:59+00:00July 17th, 2019|Hot Topics, News|

Click here to read our statement in support of the legislation. GO2 Foundation for Lung Cancer is pleased to report the recent advancement of the Burn Pits Accountability Act. We strongly support this legislation as a first step to ensure that all those affected by burn pit toxins are accounted for, in order to call for further research focused on these veterans. Since the Persian Gulf War, a common waste disposal practice at military sites outside the United States was [...]

Lung Cancer News from the Largest Oncology Meeting

2019-07-15T19:43:44+00:00July 15th, 2019|Hot Topics, News|

Don't miss our next Lung Cancer Living Room! Join us Tuesday, July 16 at 5:30 pm (PT) to discuss the best of ASCO 2019 with Dr. Jacob Sands of Dana-Farber Cancer Institute. Watch on Facebook Live, YouTube, or the Living Room Library.  The GO2 Science and Research team just returned from the 2019 American Society of Clinical Oncology (ASCO) meeting. We connect you and your loved ones to the latest research and treatment options by keeping up with [...]

New Treatment Approved for Metastatic Small Cell Lung Cancer

2019-06-18T21:13:13+00:00June 18th, 2019|Hot Topics, News|

On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option for non-small cell lung cancer, this is the first approval of pembrolizumab for small cell lung cancer. This approval was based on two clinical trials, KEYNOTE-158 and KEYNOTE-028, which measured tumor [...]

Early Screening Equals Early Diagnosis

2019-06-18T16:14:25+00:00June 18th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer’s recently published scientific paper found that lung cancer screening programs can successfully detect lung cancer early with the majority of lung cancers diagnosed at stage 1 or limited stage. Importantly, outcomes at academic and nonacademic sites were compared and the data confirmed that responsible screening can take place in a community setting. Figure B: Percentage of each stage and type of lung cancer diagnosed at nonacademic centers compared with academic centers. Published in [...]

Latest Update to Lung-RADS (1.1) is Complete!

2019-06-14T17:25:11+00:00May 23rd, 2019|Hot Topics, News|

Over the weekend, the long-awaited update of Lung-RADS was published with changes that aim to reduce lung cancer screening false positives by downgrading many category 3 findings to category 2. Lung-RADS (lung imaging reporting and data system) is a quality assurance tool to aid with findings in low-dose CT screenings for lung cancer. First introduced in 2014 by the American College of Radiology, Lung-RADS aims to standardize recommendations, reduce confusion in screening interpretations, and facilitate outcome monitoring. Here are the [...]

Patient Voices Were Heard: Preserving Access to Life Saving Drug Therapies!

2019-05-21T16:16:21+00:00May 21st, 2019|Hot Topics, News|

On May 17, 2019, The Centers for Medicare & Medicaid Services (CMS) released the final Medicare Part D Rule, where they decided to preserve the original Six Protected Classes policy. GO2 Foundation for Lung Cancer (formerly Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) advocated to stop the initial proposal that would have excluded certain drugs, including the Six Protected Classes from the Medicare Plan formularies. The Six Protected Classes policy was established over a decade ago to [...]

Research Wins Big

2019-05-17T16:57:20+00:00May 7th, 2019|Hot Topics, News|

The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care”—individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for patients. We [...]

FDA Approves First-Line Treatment for NSCLC with PD-L1 Biomarker

2019-04-12T17:39:26+00:00April 12th, 2019|Hot Topics, News|

On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.

Priority Focus Renewed on Women’s Health Imperative – House and Senate Leaders Reintroduce Women and Lung Cancer Research and Preventive Services Act of 2019

2019-04-10T19:48:13+00:00April 10th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer hails bipartisan effort to accelerate progress to increase survivorship April 10, 2019 - Today the GO2 Foundation for Lung Cancer praises Senators Marco Rubio (R-FL), Dianne Feinstein (D-CA), Shelley Moore Capito (R-WV), and Joe Manchin (D-WV), and Representatives Brendan Boyle (D-PA), Brian Fitzpatrick (R-PA), Debbie Dingell (D-MI), and Suzanne Bonamici (D-OR) for elevating national attention to a women’s public health imperative by re-introducing the 2018 Senate and House bills (S. 2358 and H.R. 4897) as the Women [...]

Transforming Cancer Care

2019-04-03T20:21:17+00:00April 3rd, 2019|Hot Topics, News|

The landscape of cancer care is changing at a rapid pace with more research and treatment options than ever before. As exciting as these advancements are, the community standing by each cancer patient is equally important. Medical professionals, families, friends, advocates and organizations offering support services all play a crucial role in a survivor’s cancer journey. Our President and CEO, Laurie Fenton Ambrose, shared her perspective with The Washington Post on why community and partnerships are key to better cancer care. [...]